# Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

> **NCT07654361** · PHASE3 · RECRUITING · sponsor: **Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics** · enrollment: 3600 (estimated)

## Conditions studied

- Obesity
- Overweight
- Chronic Weight Management

## Interventions

- **DRUG:** Aleniglipron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07654361
- **Lead sponsor:** Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-13
- **Primary completion:** 2028-09
- **Final completion:** 2028-11
- **Target enrollment:** 3600 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07654361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07654361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*